ArticleBiomarker research2018
NKX2.2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors.
Article in Biomarker research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Role of Nkx2.2 immunohistochemistry in distinguishing Ewing sarcoma from neuroendocrine neoplasms at different sites.Journal of Taibah University Medical Sciences · 2026Article
- Article
- Extended Hormone Profiling Identifies a Wider Network of Duodenal Neuroendocrine Tumor Subtypes.Endocrine pathology · 2025Article
- Review
- Systemic metastases in large cell neuroendocrine prostate cancer: a rare case report and literature review.Frontiers in oncology · 2024Article
- Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors.Endocrine pathology · 2023Article
- mRNA profiling of a well-differentiated G1 pancreatic NET correlates with immunohistochemistry profile: a case report.BMC gastroenterology · 2021Article
- Predicting the Survival Probability of Neuroendocrine Tumor Populations: Developing and Evaluating a New Predictive Nomogram.BioMed research international · 2021Article
- A primary neuroendocrine tumor of the left ventricle presenting with diarrhea-an unusual experience and literature review.Diagnostic pathology · 2020Review
- Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms.Endocrine reviews · 2020Review
- NK homeobox 2.2 functions as tumor suppressor in colorectal cancer due to DNA methylation.Journal of Cancer · 2020Article
- Neuroendocrine Liver Metastasis-a Specific Set of Markers to Detect Primary Tumor Sites.Endocrine pathology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWell-differentiated neuroendocrine tumors (NET) most frequently arise from the gastrointestinal tract (GI), pancreas, and lung. Patients often present as metastasis with an unknown primary, and the clinical management and outcome depend on multiple factors, including the accurate diagnosis with the tumor primary site. Determining the site of the NET with unknown primary remains challenging. Many biomarkers have been investigated in primary NETs and metastatic NETs, with heterogeneous sensitivity and specificity observed.
methodsWe used high-throughput tissue microarray (TMA) and immunohistochemistry (IHC) with antibodies against a panel of transcriptional factors including NKX2.2, PDX-1, PTF1A, and CDX-2 on archived formalin-fixed paraffin-embedded NETs, and investigated the protein expression pattern of these transcription factors in 109 primary GI (
resultsDifferential expression pattern of these markers was observed. In the GI and pancreatic NETs (
conclusionsOur findings suggest that NKX2.2 was a sensitive and specific biomarker for the GI and pancreatic neuroendocrine tumors. We proposed that a panel of immunostains including NKX2.2, PDX-1, and CDX-2 may show diagnostic utility for the most common NETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.